VXA-NVV-104

VXA-NVV-104 is an investigational **oral norovirus vaccine** developed by **Vaxart** that uses a **replication-defective adenovirus serotype 5 vector** to deliver norovirus antigens and induce protective immunity against norovirus-associated acute gastroenteritis. The product is formulated as an **oral tablet** and is intended to stimulate both **systemic and mucosal immune responses**, a key feature for protection at the gastrointestinal mucosa where norovirus infection is initiated. Based on the provided context, VXA-NVV-104 was evaluated in a **completed Phase 1b clinical trial** assessing safety and immunogenicity and appears to represent a program-specific study designation within Vaxart's oral norovirus vaccine portfolio.

Other names

oral norovirus vaccineAd5-based oral norovirus vaccineAd-5-based oral norovirus vaccineAd 5-based oral norovirus vaccine